Caribou Biosciences (CRBU) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | 38.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.76% |
| Dec 31, 2025 | 26.81% |
| Sep 30, 2025 | 23.11% |
| Jun 30, 2025 | -9.37% |
| Mar 31, 2025 | 6.71% |
| Dec 31, 2024 | -3.83% |
| Sep 30, 2024 | -161.31% |
| Jun 30, 2024 | -32.35% |
| Mar 31, 2024 | -47.84% |
| Dec 31, 2023 | -22.45% |
| Sep 30, 2023 | 44.86% |
| Jun 30, 2023 | -15.61% |
| Mar 31, 2023 | -49.22% |
| Dec 31, 2022 | -65.47% |
| Sep 30, 2022 | -26.52% |
| Jun 30, 2022 | -98.67% |
| Mar 31, 2022 | -58.47% |
| Dec 31, 2021 | -25.68% |
| Sep 30, 2021 | -164.39% |
| Jun 30, 2021 | -664.48% |
| Mar 31, 2021 | -34.28% |